Information Provided By: 
Fly News Breaks for April 6, 2017
ABMD
Apr 6, 2017 | 05:29 EDT
Piper Jaffray analyst Matt O'Brien upgraded Abiomed to Overweight upon assuming coverage of the name. The company's premium valuation is warranted give its "strong revenue growth outlook, non-existent competition, and considerable earnings power," O'Brien tells investors in a research note. He encourages investors to start or build positions in the name and upped his price target for the shares to $145 from $101.
News For ABMD From the Last 2 Days
There are no results for your query ABMD
